Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 21
Filtrar
1.
Pediatr Res ; 89(1): 143-149, 2021 01.
Artículo en Inglés | MEDLINE | ID: mdl-32305038

RESUMEN

BACKGROUND: Increasing evidence suggests that postnatal overfeeding induces childhood obesity, which is strongly associated with metabolic syndrome. Insulin resistance is a risk factor for metabolic syndrome. MicroRNA-221 (miR-221) is involved in the development of obesity and has been reported to negatively regulate insulin sensitivity. However, the underlying mechanism remains unclear. METHODS: Rats raised in small litters (SLs, three pups/dam, n = 10) and normal litters (NLs, 10 pups/dam, n = 10) were used to model early postnatal overfeeding and act as controls, respectively. miR-221 and proteins related to the phosphoinositide 3-kinases (PI3K)/protein kinase B (AKT) pathway were assessed in the liver. RESULTS: Early postnatal overfeeding significantly increased body weight, visceral fat index, blood glucose, serum triglycerides, and the homeostasis model assessment of insulin resistance at 9 weeks. Real-time polymerase chain reaction (PCR) and western blot analysis revealed that postnatal overfeeding induced insulin receptor and insulin receptor substrate 2 expression, but decreased PI3K and AKT phosphorylation in the liver. Quantitative real-time PCR showed that hepatic miR-221 was significantly overexpressed in the SL group. CONCLUSIONS: These results indicate that postnatal overfeeding induces hepatic miR-221 overexpression and impairs the PI3K/AKT signal pathway, which may cause insulin resistance. IMPACT: We first report postnatal overfeeding induces hepatic miR-221 expression. Postnatal overfeeding impairs PI3K/AKT pathway in the liver of adult rats. Postnatal overfeeding induces obesity and high blood glucose. Avoidance of overfeeding during early postnatal life may prevent obesity and T2DM.


Asunto(s)
Hiperfagia/enzimología , Resistencia a la Insulina , Hígado/enzimología , MicroARNs/metabolismo , Obesidad/enzimología , Fosfatidilinositol 3-Quinasa/metabolismo , Proteínas Proto-Oncogénicas c-akt/metabolismo , Adiposidad , Animales , Modelos Animales de Enfermedad , Hiperfagia/genética , Hiperfagia/patología , Proteínas Sustrato del Receptor de Insulina/genética , Proteínas Sustrato del Receptor de Insulina/metabolismo , Resistencia a la Insulina/genética , Hígado/patología , Masculino , MicroARNs/genética , Obesidad/genética , Obesidad/patología , Fosfatidilinositol 3-Quinasa/genética , Fosforilación , Ratas Sprague-Dawley , Receptor de Insulina/genética , Receptor de Insulina/metabolismo , Transducción de Señal , Aumento de Peso
2.
Nature ; 538(7624): 253-256, 2016 Oct 13.
Artículo en Inglés | MEDLINE | ID: mdl-27698417

RESUMEN

Atypical food intake is a primary cause of obesity and other eating and metabolic disorders. Insight into the neural control of feeding has previously focused mainly on signalling mechanisms associated with the hypothalamus, the major centre in the brain that regulates body weight homeostasis. However, roles of non-canonical central nervous system signalling mechanisms in regulating feeding behaviour have been largely uncharacterized. Acetylcholine has long been proposed to influence feeding owing in part to the functional similarity between acetylcholine and nicotine, a known appetite suppressant. Nicotine is an exogenous agonist for acetylcholine receptors, suggesting that endogenous cholinergic signalling may play a part in normal physiological regulation of feeding. However, it remains unclear how cholinergic neurons in the brain regulate food intake. Here we report that cholinergic neurons of the mouse basal forebrain potently influence food intake and body weight. Impairment of cholinergic signalling increases food intake and results in severe obesity, whereas enhanced cholinergic signalling decreases food consumption. We found that cholinergic circuits modulate appetite suppression on downstream targets in the hypothalamus. Together our data reveal the cholinergic basal forebrain as a major modulatory centre underlying feeding behaviour.


Asunto(s)
Regulación del Apetito/fisiología , Prosencéfalo Basal/citología , Prosencéfalo Basal/fisiología , Neuronas Colinérgicas/metabolismo , Conducta Alimentaria/fisiología , Respuesta de Saciedad/fisiología , Acetilcolina/metabolismo , Animales , Peso Corporal/fisiología , Muerte Celular , Colina O-Acetiltransferasa/deficiencia , Agonistas Colinérgicos , Neuronas Colinérgicas/patología , Ingestión de Alimentos/fisiología , Ingestión de Alimentos/psicología , Conducta Alimentaria/psicología , Femenino , Homeostasis , Hiperfagia/enzimología , Hiperfagia/genética , Hiperfagia/patología , Hipotálamo/citología , Hipotálamo/fisiología , Masculino , Ratones , Ratones Noqueados , Modelos Neurológicos , Nicotina/metabolismo , Obesidad/enzimología , Obesidad/genética , Obesidad/patología , Receptores Colinérgicos/metabolismo
3.
Cell Metab ; 23(5): 821-36, 2016 May 10.
Artículo en Inglés | MEDLINE | ID: mdl-27133129

RESUMEN

Despite significant advances in our understanding of the biology determining systemic energy homeostasis, the treatment of obesity remains a medical challenge. Activation of AMP-activated protein kinase (AMPK) has been proposed as an attractive strategy for the treatment of obesity and its complications. AMPK is a conserved, ubiquitously expressed, heterotrimeric serine/threonine kinase whose short-term activation has multiple beneficial metabolic effects. Whether these translate into long-term benefits for obesity and its complications is unknown. Here, we observe that mice with chronic AMPK activation, resulting from mutation of the AMPK γ2 subunit, exhibit ghrelin signaling-dependent hyperphagia, obesity, and impaired pancreatic islet insulin secretion. Humans bearing the homologous mutation manifest a congruent phenotype. Our studies highlight that long-term AMPK activation throughout all tissues can have adverse metabolic consequences, with implications for pharmacological strategies seeking to chronically activate AMPK systemically to treat metabolic disease.


Asunto(s)
Proteínas Quinasas Activadas por AMP/metabolismo , Células Secretoras de Insulina/enzimología , Células Secretoras de Insulina/patología , Obesidad/enzimología , Adiposidad/genética , Adulto , Envejecimiento/patología , Proteína Relacionada con Agouti/metabolismo , Animales , Núcleo Arqueado del Hipotálamo/metabolismo , Metabolismo Energético/genética , Activación Enzimática , Conducta Alimentaria , Femenino , Heterocigoto , Humanos , Hiperfagia/complicaciones , Hiperfagia/enzimología , Hiperfagia/genética , Hiperfagia/patología , Hipotálamo/metabolismo , Insulina/metabolismo , Masculino , Ratones , Mitocondrias/metabolismo , Mutación/genética , Neuronas/metabolismo , Obesidad/sangre , Obesidad/complicaciones , Obesidad/patología , Fosforilación Oxidativa , Receptores de Ghrelina/metabolismo , Ribosomas/metabolismo , Transducción de Señal/genética , Transcriptoma/genética , Regulación hacia Arriba/genética
4.
PLoS One ; 9(5): e97195, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-24819600

RESUMEN

Lipid metabolism in the ventromedial hypothalamus (VMH) has emerged as a crucial pathway in the regulation of feeding and energy homeostasis. Carnitine palmitoyltransferase (CPT) 1A is the rate-limiting enzyme in mitochondrial fatty acid ß-oxidation and it has been proposed as a crucial mediator of fasting and ghrelin orexigenic signalling. However, the relationship between changes in CPT1A activity and the intracellular downstream effectors in the VMH that contribute to appetite modulation is not fully understood. To this end, we examined the effect of long-term expression of a permanently activated CPT1A isoform by using an adeno-associated viral vector injected into the VMH of rats. Peripherally, this procedure provoked hyperghrelinemia and hyperphagia, which led to overweight, hyperglycemia and insulin resistance. In the mediobasal hypothalamus (MBH), long-term CPT1AM expression in the VMH did not modify acyl-CoA or malonyl-CoA levels. However, it altered the MBH lipidomic profile since ceramides and sphingolipids increased and phospholipids decreased. Furthermore, we detected increased vesicular γ-aminobutyric acid transporter (VGAT) and reduced vesicular glutamate transporter 2 (VGLUT2) expressions, both transporters involved in this orexigenic signal. Taken together, these observations indicate that CPT1A contributes to the regulation of feeding by modulating the expression of neurotransmitter transporters and lipid components that influence the orexigenic pathways in VMH.


Asunto(s)
Carnitina O-Palmitoiltransferasa/genética , Hiperfagia/genética , Hiperfagia/metabolismo , Metabolismo de los Lípidos/genética , Núcleo Hipotalámico Ventromedial/metabolismo , Animales , Regulación del Apetito/genética , Carnitina O-Palmitoiltransferasa/metabolismo , Dependovirus/genética , Ingestión de Alimentos/genética , Expresión Génica , Vectores Genéticos/genética , Hiperglucemia/enzimología , Hiperglucemia/genética , Hiperfagia/enzimología , Resistencia a la Insulina/genética , Isoenzimas/genética , Isoenzimas/metabolismo , Masculino , Obesidad/enzimología , Obesidad/genética , ARN Mensajero/genética , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Núcleo Hipotalámico Ventromedial/fisiopatología
5.
J Appl Physiol (1985) ; 116(9): 1156-64, 2014 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-24577062

RESUMEN

We tested the hypothesis that nonalcoholic fatty liver disease (NAFLD) is associated with reduced hepatic endothelial nitric oxide synthase (eNOS) activation status via S1177 phosphorylation (p-eNOS) and is prevented by daily voluntary wheel running (VWR). Hyperphagic Otsuka Long-Evans Tokushima Fatty (OLETF) rats, an established model of obesity, type 2 diabetes (T2D) and NAFLD, and normophagic controls [Long-Evans Tokushima Otsuka (LETO)] were studied at 8, 20, and 40 wk of age. Basal hepatic eNOS phosphorylation (p-eNOS/eNOS) was similar between LETO and OLETFs with early hepatic steatosis (8 wk of age) and advanced steatosis, hyperinsulinemia, and hyperglycemia (20 wk of age). In contrast, hepatic p-eNOS/eNOS was significantly lower (P < 0.05) in OLETF rats with T2D advancement and the transition to more advanced NAFLD with inflammation and fibrosis [increased tumor necrosis factor-α (TNF-α), CD68, and CD163 mRNA expression; 40 wk of age]. Reduced hepatic eNOS activation status in 40-wk OLETF rats was significantly correlated with reduced p-Akt/Akt (r = 0.73, P < 0.05), reduced serum insulin (r = 0.59, P < 0.05), and elevated serum glucose (r = -0.78, P < 0.05), suggesting a link between impaired glycemic control and altered hepatic nitric oxide metabolism. VWR by OLETF rats, in conjunction with NAFLD and T2D prevention, normalized p-eNOS/eNOS and p-Akt/Akt to LETO levels. Basal activation of hepatic eNOS and Akt are maintained until advanced NAFLD and T2D development in obese OLETF rats. The prevention of this reduction by VWR may result from maintained insulin sensitivity and glycemic control.


Asunto(s)
Diabetes Mellitus Tipo 2/enzimología , Progresión de la Enfermedad , Hiperfagia/enzimología , Óxido Nítrico Sintasa de Tipo III/metabolismo , Enfermedad del Hígado Graso no Alcohólico/enzimología , Condicionamiento Físico Animal/fisiología , Animales , Diabetes Mellitus Tipo 2/prevención & control , Hiperfagia/prevención & control , Hígado/enzimología , Masculino , Enfermedad del Hígado Graso no Alcohólico/prevención & control , Fosforilación/fisiología , Condicionamiento Físico Animal/métodos , Distribución Aleatoria , Ratas , Ratas Endogámicas OLETF
6.
J Pathol ; 227(2): 209-22, 2012 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22294347

RESUMEN

Hyperthyroidism is characterized in rats by increased energy expenditure and marked hyperphagia. Alterations of thermogenesis linked to hyperthyroidism are associated with dysregulation of hypothalamic AMPK and fatty acid metabolism; however, the central mechanisms mediating hyperthyroidism-induced hyperphagia remain largely unclear. Here, we demonstrate that hyperthyroid rats exhibit marked up-regulation of the hypothalamic mammalian target of rapamycin (mTOR) signalling pathway associated with increased mRNA levels of agouti-related protein (AgRP) and neuropeptide Y (NPY), and decreased mRNA levels of pro-opiomelanocortin (POMC) in the arcuate nucleus of the hypothalamus (ARC), an area where mTOR co-localizes with thyroid hormone receptor-α (TRα). Central administration of thyroid hormone (T3) or genetic activation of thyroid hormone signalling in the ARC recapitulated hyperthyroidism effects on feeding and the mTOR pathway. In turn, central inhibition of mTOR signalling with rapamycin in hyperthyroid rats reversed hyperphagia and normalized the expression of ARC-derived neuropeptides, resulting in substantial body weight loss. The data indicate that in the hyperthyroid state, increased feeding is associated with thyroid hormone-induced up-regulation of mTOR signalling. Furthermore, our findings that different neuronal modulations influence food intake and energy expenditure in hyperthyroidism pave the way for a more rational design of specific and selective therapeutic compounds aimed at reversing the metabolic consequences of this disease.


Asunto(s)
Ingestión de Alimentos , Conducta Alimentaria , Hiperfagia/etiología , Hipertiroidismo/complicaciones , Hipotálamo/enzimología , Transducción de Señal , Serina-Treonina Quinasas TOR/metabolismo , Proteínas Quinasas Activadas por AMP/metabolismo , Proteína Relacionada con Agouti/genética , Animales , Modelos Animales de Enfermedad , Ingestión de Alimentos/efectos de los fármacos , Conducta Alimentaria/efectos de los fármacos , Hiperfagia/enzimología , Hiperfagia/genética , Hiperfagia/fisiopatología , Hiperfagia/prevención & control , Hipertiroidismo/inducido químicamente , Hipertiroidismo/enzimología , Hipertiroidismo/genética , Hipertiroidismo/fisiopatología , Hipotálamo/efectos de los fármacos , Hipotálamo/fisiopatología , Masculino , Vías Nerviosas/efectos de los fármacos , Vías Nerviosas/enzimología , Neuropéptido Y/genética , Fosforilación , Proopiomelanocortina/genética , Inhibidores de Proteínas Quinasas/farmacología , ARN Mensajero/metabolismo , Ratas , Ratas Sprague-Dawley , Transducción de Señal/efectos de los fármacos , Sirolimus/farmacología , Serina-Treonina Quinasas TOR/antagonistas & inhibidores , Receptores alfa de Hormona Tiroidea/metabolismo , Factores de Tiempo , Triyodotironina , Pérdida de Peso
7.
Sleep ; 33(3): 307-14, 2010 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-20337188

RESUMEN

BACKGROUND: A genetic deficiency in sepiapterin reductase leads to a combined deficit of serotonin and dopamine. The motor phenotype is characterized by a dopa-responsive fluctuating generalized dystonia-parkinsonism. The non-motor symptoms are poorly recognized. In particular, the effects of brain serotonin deficiency on sleep have not been thoroughly studied. OBJECTIVE: We examine the sleep, sleep-wake rhythms, CSF neurotransmitters, and melatonin profile in a patient with sepiapterin reductase deficiency. PATIENT: The patient was a 28-year-old man with fluctuating generalized dystonia-parkinsonism caused by sepiapterin reductase deficiency. METHODS: A sleep interview, wrist actigraphy, sleep log over 14 days, 48-h continuous sleep and core temperature monitoring, and measurement of CSF neurotransmitters and circadian serum melatonin and cortisol levels before and after treatment with 5-hydroxytryptophan (the precursor of serotonin) and levodopa were performed. RESULTS: Before treatment, the patient had mild hypersomnia with long sleep time (704 min), ultradian sleep-wake rhythm (sleep occurred every 11.8 +/- 5.3 h), organic hyperphagia, attentionlexecutive dysfunction, and no depression. The serotonin metabolism in the CSF was reduced, and the serum melatonin profile was flat, while cortisol and core temperature profiles were normal. Supplementation with 5-hydroxytryptophan, but not with levodopa, normalized serotonin metabolism in the CSF, reduced sleep time to 540 min, normalized the eating disorder and the melatonin profile, restored a circadian sleep-wake rhythm (sleep occurred every 24 +/- 1.7 h, P < 0.0001), and improved cognition. CONCLUSION: In this unique genetic paradigm, the melatonin deficiency (caused by a lack of its substrate, serotonin) may cause the ultradian sleep-wake rhythm.


Asunto(s)
Oxidorreductasas de Alcohol/deficiencia , Oxidorreductasas de Alcohol/genética , Trastornos de Somnolencia Excesiva/genética , Serotonina/deficiencia , Trastornos del Sueño del Ritmo Circadiano/genética , Sueño/genética , 5-Hidroxitriptófano/uso terapéutico , Adulto , Antidepresivos de Segunda Generación/uso terapéutico , Consanguinidad , Trastornos de Somnolencia Excesiva/tratamiento farmacológico , Trastornos de Somnolencia Excesiva/enzimología , Dopamina/deficiencia , Dopaminérgicos/uso terapéutico , Quimioterapia Combinada , Humanos , Hidrocortisona/sangre , Hiperfagia/tratamiento farmacológico , Hiperfagia/enzimología , Hiperfagia/genética , Levodopa/uso terapéutico , Masculino , Melatonina/deficiencia , Polisomnografía , Sueño/efectos de los fármacos , Trastornos del Sueño del Ritmo Circadiano/tratamiento farmacológico , Trastornos del Sueño del Ritmo Circadiano/enzimología
8.
Cell Metab ; 9(4): 362-74, 2009 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-19356717

RESUMEN

The mammalian target of rapamycin (mTOR) promotes anabolic cellular processes in response to growth factors and metabolic cues. The TSC1 and TSC2 tumor suppressors are major upstream inhibitory regulators of mTOR signaling. Mice with Rip2/Cre-mediated deletion of Tsc1 (Rip-Tsc1cKO mice) developed hyperphagia and obesity, suggesting that hypothalamic disruption (for which Rip2/Cre is well known) of Tsc1 may dysregulate feeding circuits via mTOR activation. Indeed, Rip-Tsc1cKO mice displayed increased mTOR signaling and enlarged neuron cell size in a number of hypothalamic populations, including Pomc neurons. Furthermore, Tsc1 deletion with Pomc/Cre (Pomc-Tsc1cKO mice) resulted in dysregulation of Pomc neurons and hyperphagic obesity. Treatment with the mTOR inhibitor, rapamycin, ameliorated the hyperphagia, obesity, and the altered Pomc neuronal morphology in developing or adult Pomc-Tsc1cKO mice, and cessation of treatment reinstated these phenotypes. Thus, ongoing mTOR activation in Pomc neurons blocks the catabolic function of these neurons to promote nutrient intake and increased adiposity.


Asunto(s)
Metabolismo Energético , Hipotálamo/enzimología , Proteínas Quinasas/metabolismo , Animales , Metabolismo Energético/efectos de los fármacos , Eliminación de Gen , Hiperfagia/complicaciones , Hiperfagia/enzimología , Hipotálamo/efectos de los fármacos , Hipotálamo/patología , Melanocortinas/metabolismo , Ratones , Ratones Noqueados , Neuronas/efectos de los fármacos , Neuronas/enzimología , Neuronas/patología , Obesidad/complicaciones , Obesidad/enzimología , Proopiomelanocortina/metabolismo , Proteína Serina-Treonina Quinasa 2 de Interacción con Receptor , Proteína Serina-Treonina Quinasas de Interacción con Receptores/metabolismo , Sirolimus/farmacología , Serina-Treonina Quinasas TOR , Proteína 1 del Complejo de la Esclerosis Tuberosa , Proteínas Supresoras de Tumor/metabolismo
9.
Endocrinology ; 147(9): 4486-95, 2006 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-16763061

RESUMEN

11 beta-Hydroxysteroid dehydrogenase type 1 (11 beta-HSD1) catalyzes regeneration of active intracellular glucocorticoids in fat, liver, and discrete brain regions. Although overexpression of 11 beta-HSD1 in adipose tissue causes hyperphagia and the metabolic syndrome, male 11 beta-HSD1 null (11 beta-HSD1-/-) mice resist metabolic disease on high-fat (HF) diet, but also show hyperphagia. This suggests 11 beta-HSD1 may influence the central actions of glucocorticoids on appetite and perhaps energy balance. We show that 11 beta-HSD1-/- mice express lower hypothalamic mRNA levels of the anorexigenic cocaine and amphetamine-regulated transcript and melanocortin-4 receptor, but higher levels of the orexigenic melanin-concentrating hormone mRNAs than controls (C57BL/6J) on a low-fat diet (11% fat). HF (58% fat) diet promoted transient ( approximately 8 wk) hyperphagia and decreased food efficiency in 11 beta-HSD1-/- mice and decreased melanocortin-4 receptor mRNA expression in control but not 11 beta-HSD1-/- mice. 11 beta-HSD1-/- mice showed a HF-mediated up-regulation of the orexigenic agouti-related peptide (AGRP) mRNA in the arcuate nucleus which paralleled the transient HF hyperphagia. Conversely, control mice showed a rapid (48 h) HF-mediated increase in arcuate 11 beta-HSD1 associated with subsequent down-regulation of AGRP. This regulatory pattern was unexpected because glucocorticoids increase AGRP, suggesting an alternate hyperphagic mechanism despite partial colocalization of 11 beta-HSD1 and AGRP in arcuate nucleus cells. One major alternate mechanism governing selective fat ingestion and the AGRP system is endogenous opioids. Treatment of HF-fed mice with the mu opioid agonist DAMGO recapitulated the HF-induced dissociation of arcuate AGRP expression between control and 11 beta-HSD1-/- mice, whereas the opioid antagonist naloxone given with HF induced a rise in arcuate AGRP and blocked HF-diet induction of 11 beta-HSD1. These data suggest that 11 beta-HSD1 in brain plays a role in the adaptive restraint of excess fat intake, in part by increasing inhibitory opioid tone on AGRP expression in the arcuate nucleus.


Asunto(s)
11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1/biosíntesis , Núcleo Arqueado del Hipotálamo/enzimología , Grasas de la Dieta/administración & dosificación , Hiperfagia/enzimología , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1/deficiencia , 11-beta-Hidroxiesteroide Deshidrogenasa de Tipo 1/genética , Proteína Relacionada con Agouti , Animales , Corticosterona/sangre , Encefalina Ala(2)-MeFe(4)-Gli(5)/farmacología , Inducción Enzimática , Femenino , Expresión Génica , Insulina/sangre , Péptidos y Proteínas de Señalización Intercelular , Leptina/sangre , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas del Tejido Nervioso/genética , Neuronas/química , Neuropéptido Y/genética , Proopiomelanocortina/genética , Proteínas/genética , ARN Mensajero/análisis , Receptor de Melanocortina Tipo 4/genética , Receptores Opioides mu/agonistas , Hormonas Tiroideas/sangre , Aumento de Peso
10.
Diabetes ; 54(1): 63-8, 2005 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-15616011

RESUMEN

AMP-activated protein kinase (AMPK) acts as a cellular energy sensor, being activated during states of low energy charge. Hypothalamic AMPK activity is altered by hormonal and metabolic signals and mediates the feeding response. To determine the effect of diabetes on hypothalamic AMPK activity, we assayed this activity in streptozotocin (STZ)-induced diabetic rats. Compared with control rats, STZ-induced diabetic rats had significant hyperphagia and weight loss. Hypothalamic AMPK phosphorylation and alpha2-AMPK activity were higher and acetyl-CoA carboxylase activity was lower in diabetic rats than in control rats. Chronic insulin treatment or suppression of hypothalamic AMPK activity completely prevented diabetes-induced changes in food intake as well as in hypothalamic AMPK activity and mRNA expression of neuropeptide Y and proopiomelanocortin. Plasma leptin and insulin levels were profoundly decreased in diabetic rats. Intracerebroventricular administration of leptin and insulin reduced hyperphagia and the enhanced hypothalamic AMPK activity in diabetic rats. These data suggest that leptin and insulin deficiencies in diabetes lead to increased hypothalamic AMPK activity, which contributes to the development of diabetic hyperphagia.


Asunto(s)
Diabetes Mellitus Experimental/enzimología , Hiperfagia/enzimología , Hipotálamo/enzimología , Hipotálamo/fisiopatología , Complejos Multienzimáticos/metabolismo , Proteínas Serina-Treonina Quinasas/metabolismo , Proteínas Quinasas Activadas por AMP , Tejido Adiposo/anatomía & histología , Animales , Ingestión de Energía , Técnicas de Transferencia de Gen , Genes myc/genética , Insulina/sangre , Leptina/sangre , Masculino , Tamaño de los Órganos , Fosforilación , Ratas , Ratas Sprague-Dawley , Pérdida de Peso
11.
Am J Physiol Endocrinol Metab ; 284(1): E213-8, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12388146

RESUMEN

Mice lacking acyl-CoA:diacylglycerol acyltransferase 1 (DGAT1), a key enzyme in triglyceride synthesis, have increased energy expenditure and therefore are resistant to obesity. Because ambient temperature can significantly affect energy expenditure in mice, we undertook these studies to determine the effects of different ambient temperatures on energy expenditure, food intake, and thermoregulation in DGAT1-deficient [Dgat1(-/-)] mice. Dgat1(-/-) mice had increased energy expenditure irrespective of changes in the ambient temperature. Although core temperature was normal, surface temperature was increased in Dgat1(-/-) mice, most likely reflecting an active mechanism to dissipate heat from increased thermogenesis. Dgat1(-/-) mice had increased food intake at baseline, and this hyperphagia became more pronounced upon exposure to cold. When fasted in a cold environment, Dgat1(-/-) mice developed hypothermia, which was associated with hypoglycemia. These results suggest that the hyperphagia in Dgat1(-/-) mice is a secondary mechanism that compensates for the increased utilization of fuel substrates. Our findings offer insights into the mechanisms of hyperphagia and increased energy expenditure in a murine model of obesity resistance.


Asunto(s)
Aciltransferasas/deficiencia , Metabolismo Energético , Temperatura , Aciltransferasas/genética , Aciltransferasas/fisiología , Animales , Glucemia/metabolismo , Temperatura Corporal , Regulación de la Temperatura Corporal , Proteínas Portadoras/genética , Frío , Diacilglicerol O-Acetiltransferasa , Ingestión de Alimentos , Ayuno , Femenino , Expresión Génica , Glucógeno/análisis , Hiperfagia/enzimología , Hipoglucemia/enzimología , Hipotermia/enzimología , Canales Iónicos , Hígado/química , Proteínas de la Membrana/genética , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Proteínas Mitocondriales , Músculo Esquelético/química , Obesidad/enzimología , Proteína Desacopladora 1 , Pérdida de Peso
12.
Life Sci ; 58(1): PL9-15, 1996.
Artículo en Inglés | MEDLINE | ID: mdl-8628105

RESUMEN

The presence of a nitric oxide synthetase (NOS) was demonstrated in the rat brain. It has been demonstrated recently that NOS-inhibitors reduce food intake in mammals and this suggest that nitric oxide (NO) might be a physiological mediator involved in the mechanisms controlling feeding behavior. Actually, there is no information about the acute central and peripheral effects of NOS-inhibitors on feeding behavior in obese and lean Zucker rats. That is why we investigated the acute dose-dependent activity of NG-Nitro-Arginine-Methyl-Ester (L-NAME) on food intake and feeding behavior in these rats. When given peripherally in the obese rats, L-NAME produced a dose-dependent decrease in food intake (p<0.001). The calculated MED and the ED 50 were 0.50 mg/kg IP and 3.46 mg/kg IP, respectively. These effects could not be reproduced in the lean Zucker rats whatever the dose used (p=0.59). The anorectic properties of L-NAME were very well translated into the microstructure of the feeding behavior. Time spent to eat (p<0.001), meal duration (p<0.01) and meal number (p<0.01) were reduced in the obese rats. Interestingly, L-NAME produced the same effects in the lean rats, but meal size increased in a compensatory manner. Central administration of L-NAME reproduced the same effects in the obese rats, but lean rats still remained insensitive. Central aminergic and/or peptidergic defects associated with the expression of hyperphagia might explain the differences observed between these lean and the obese animals. These results indicate a role of nitric oxide in the expression of hyperphagia and show that it might be a physiological mediator involved in the mechanisms controlling feeding behavior.


Asunto(s)
Conducta Alimentaria/fisiología , Hiperfagia/fisiopatología , Óxido Nítrico/fisiología , Obesidad/fisiopatología , Animales , Arginina/análogos & derivados , Arginina/farmacología , Peso Corporal/fisiología , Relación Dosis-Respuesta a Droga , Ingestión de Alimentos/efectos de los fármacos , Inhibidores Enzimáticos/farmacología , Conducta Alimentaria/efectos de los fármacos , Hiperfagia/tratamiento farmacológico , Hiperfagia/enzimología , Masculino , NG-Nitroarginina Metil Éster , Óxido Nítrico Sintasa/antagonistas & inhibidores , Obesidad/tratamiento farmacológico , Obesidad/enzimología , Ratas , Ratas Zucker
13.
Drug Metab Dispos ; 21(5): 782-7, 1993.
Artículo en Inglés | MEDLINE | ID: mdl-7902236

RESUMEN

Human obesity is associated with a number of pathophysiologic processes, such as fatty infiltration and fibrosis of the liver. Although obesity has been shown to alter the metabolism of various xenobiotics, its effect on hepatic cytochromes P-450 is not known. In this study, the overfed rat was used as a model for examining the influence of obesity on the expression and regulation of hepatic cytochrome P-450 2B1/2B2. Sprague-Dawley rats were fed either a standard diet or an energy-dense diet for 32 weeks. The energy-dense diet resulted in a significant increase in body weight, serum triglyceride levels, and liver lipid content. Obesity did not influence baseline levels of spectral cytochrome P-450 content. Similar baseline activities of CYP2B1/2B2 (16 beta-testosterone hydroxylase and pentoxyresorufin O-dealkylation)--comparative protein levels of CYP2B1/2B2 (Western blot), and mRNA (slot blot)--were found in rats fed either diet. Half of the animals in each group were given 20 mg phenobarbital (intraperitoneal injection)/animal every 12 hr for three consecutive days. This resulted in similar phenobarbital plasma concentrations in both groups. Phenobarbital treatment increased the concentrations of cytochrome P-450 in both groups to the same extent. However, greater CYP2B1/2B2 activity was found in control rats following phenobarbital administration, whereas the amount of protein and mRNA was similar in each treated group. In conclusion, obesity did not affect the regulation of CYP2B1/2B2 enzymes. However, changes in the lipid environment associated with obesity may have affected the activity of these proteins.


Asunto(s)
Sistema Enzimático del Citocromo P-450/biosíntesis , Hiperfagia/enzimología , Obesidad/enzimología , Fenobarbital/farmacología , Animales , Citocromo P-450 CYP2B1 , Sistema Enzimático del Citocromo P-450/genética , Sondas de ADN , Modelos Animales de Enfermedad , Inducción Enzimática , Hiperlipidemias/enzimología , Masculino , Oxidorreductasas/biosíntesis , Oxidorreductasas/genética , ARN Mensajero/análisis , Ratas , Ratas Sprague-Dawley
14.
Int J Obes Relat Metab Disord ; 16(10): 789-99, 1992 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-1330958

RESUMEN

The activities of two distinct phosphatidate phosphohydrolases (PAP) were measured in livers, hearts and adipose tissues of the JCR:LA corpulent rat which is hyperphagic, hypertriglyceridaemic and insulin resistant. The specific activity of PAP-1, which requires Mg2+, was similar in the livers of lean and corpulent female rats and in male corpulent rats, but these activities were about 1.6-fold higher than in lean males. There was a correlation between the specific activity of PAP-1 and the concentrations of hepatic and serum triacylglycerols in the males, but not in the females. Chronic treatment of the corpulent rats with ethanol did not significantly alter the hepatic activity of PAP-1, or the concentrations of hepatic or serum triacylglycerols. Specific activities of PAP-1 in the heart were higher in the lean compared to the corpulent males. There was no significant difference for the females. Specific activities of PAP-1 were over 5-fold higher in the subcutaneous adipose tissue of the corpulent males and females compared to the lean genotypes. The differences were smaller (1.6-1.9-fold) in the gonadal adipose tissue of both sexes and in the peri-renal depot for the males. PAP-1 activity in the peri-renal depots of corpulent females was 23% lower than in lean females. PAP-2 activity was insensitive to N-ethylmaleimide and did not require Mg2+ for activity. Its activity was 1.5-2.0-fold higher in the livers and hearts of the lean male and female rats than in the corpulent genotypes. Chronic treatment with ethanol increased the activity of PAP-2 in the hearts of the corpulent males, but had no effect in the corpulent females. The specific activity of PAP-2 was higher in subcutaneous, gonadal and peri-renal adipose depots in the females and in the peri-renal depot of the corpulent males compared with the lean genotypes. Lean males had higher specific activities in all three depots compared to lean females. The tissue specificity and the sex differences in the specific activities of PAP-1 and PAP-2 are discussed in terms of their proposed functions in glycerolipid biosynthesis and signal transduction. It is proposed that a decreased activity of PAP-2 could be involved in the insulin insensitivity in the corpulent rats.


Asunto(s)
Tejido Adiposo/enzimología , Hígado/enzimología , Miocardio/enzimología , Obesidad/enzimología , Fosfatidato Fosfatasa/metabolismo , Transducción de Señal/fisiología , Animales , Etanol/farmacología , Etilmaleimida/farmacología , Femenino , Glucolípidos/biosíntesis , Hiperfagia/enzimología , Hipertrigliceridemia/enzimología , Resistencia a la Insulina , Magnesio/farmacología , Masculino , Proteínas Asociadas a Pancreatitis , Ratas , Ratas Mutantes , Triglicéridos/sangre , Triglicéridos/metabolismo
15.
Int J Obes ; 15(3): 221-5, 1991 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-2045215

RESUMEN

Changes in the components of hepatic microsomal electron transport systems and in drug hydroxylase activities were investigated in ventromedial hypothalamus (VMH) lesioned obese rats. Eight weeks after electrolysis of the bilateral VMH, the content of cytochrome P450 per mg microsomal protein (0.79 +/- 0.07 nmol/mg protein) was significantly higher (P less than 0.02) than that in the sham-operated rats (0.59 +/- 0.02). Cytochrome P450 per whole liver in the VMH-lesioned obese rats had also significantly increased (87 +/- 9 nmol vs 56 +/- 3, P less than 0.02). No significant differences were found in the cytochrome b5 contents, and the activities of NADPH- and NADH-cytochrome c reductases between the VMH-lesioned obese and sham-operated rats. The demethylation activities of aminopyrine (1.04 +/- 0.02 nmol/mg protein/min vs 0.94 +/- 0.02, P less than 0.05) and p-nitroanisole (0.96 +/- 0.02 vs 0.89 +/- 0.02 , p less than 0.02) and the aniline hydroxylase activity (0.22 +/- 0.01 vs 0.16 +/- 0.01, P less than 0.01) were enhanced, but 7-ethoxycoumarin O-deethylase activity was unchanged in the VMH-lesioned obese rats. These results indicate a selective increase in the content of cytochrome P450 among the components of the P450-dependent mixed function oxidase system in the liver of VMH-lesioned obese rats. Our observations suggest that drug metabolism may be enhanced in the hypothalamic obesity.


Asunto(s)
Sistema Enzimático del Citocromo P-450/biosíntesis , Microsomas Hepáticos/enzimología , Obesidad/enzimología , Núcleo Hipotalámico Ventromedial/fisiopatología , Animales , Glucemia/metabolismo , Peso Corporal/fisiología , Femenino , Hiperinsulinismo/enzimología , Hiperfagia/enzimología , Lípidos/sangre , Oxigenasas de Función Mixta/biosíntesis , Oxidorreductasas N-Desmetilantes/biosíntesis , Oxidorreductasas O-Demetilantes/biosíntesis , Ratas
17.
J Clin Endocrinol Metab ; 61(6): 1053-60, 1985 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-2997257

RESUMEN

Platelets alpha 2-adrenoceptors were studied in 24 patients with anorexia nervosa shortly after admission to the hospital and after 10% weight gain. Twenty patients with bulimia and 24 healthy age- and sex-matched normal subjects also were studied. Receptor number was significantly increased in patients with bulimia and anorexia nervosa. After 10% weight gain, the receptor number almost normalized in anorexia nervosa patients. Kd values were increased in all patients groups at all times of study. In patients with bulimia or anorexia nervosa, both initially and after weight gain, the maximal effect of prostaglandin E1 (PGE1) on platelet cAMP production was greatly increased, while the half-maximally effective dose was unchanged. Also, the maximal inhibitory effects of epinephrine and clonidine on PGE1-stimulated platelet cAMP production were greater, while the half-maximal dose of both alpha 2-agonists was unchanged. Metabolic and endocrine indicators of starvation were present in both bulimic and anorexia nervosa patients initially. Blood beta-hydroxybutyric acid was elevated, and plasma T3 values and the orthostatic response of plasma norepinephrine (delta NA) were reduced, while cortisol was elevated (only in anorexia nervosa patients). Among these parameters, only delta NA significantly correlated with the actions of PGE1 and epinephrine on cAMP production. In conclusion, the activity of the sympathetic nervous system was reduced in patients with anorexia nervosa and bulimia. This reduction was accompanied by an increased capacity and a decreased affinity of platelet alpha 2-receptors and an increased PGE1 stimulatory and epinephrine inhibitory effects on cAMP production.


Asunto(s)
Anorexia Nerviosa/sangre , Plaquetas/metabolismo , Trastornos de Alimentación y de la Ingestión de Alimentos/sangre , Hiperfagia/sangre , Receptores Adrenérgicos alfa/metabolismo , Inhibidores de Adenilato Ciclasa , Adenilil Ciclasas/sangre , Adolescente , Adulto , Alprostadil/farmacología , Anorexia Nerviosa/enzimología , Plaquetas/enzimología , AMP Cíclico/sangre , Activación Enzimática/efectos de los fármacos , Epinefrina/farmacología , Femenino , Humanos , Hiperfagia/enzimología
19.
Q J Med ; 54(214): 177-82, 1985 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-2580331

RESUMEN

Recent increase in the identification and treatment of bulimia, an eating disorder characterised by excessive eating and often accompanied by some form of purging behaviour, has led to an interest in its proper medical evaluation. Although scattered reports describe a multitude of associated medical complications, their true incidence is not known. We describe our experience with 39 consecutive bulimic patients who underwent thorough medical evaluation. Serious disease was rarely encountered although a significant association was found between low body weight and hypokalaemia. Elevated serum amylase values were also noted in 15 of 24 patients (62 per cent). The potential utility of the latter in treating bulimic patients is discussed. A practical approach to the management of these patients is outlined.


Asunto(s)
Trastornos de Alimentación y de la Ingestión de Alimentos/complicaciones , Hiperfagia/complicaciones , Adolescente , Adulto , Amilasas/sangre , Peso Corporal , Femenino , Hematócrito , Humanos , Hiperfagia/sangre , Hiperfagia/enzimología , Magnesio/sangre , Masculino , Potasio/sangre , Estudios Prospectivos
20.
Reprod Nutr Dev (1980) ; 23(1): 137-43, 1983.
Artículo en Inglés | MEDLINE | ID: mdl-6573735

RESUMEN

Rats fed either a low (2p. 100) or high (40 p. 100)-fat diet were exposed to 22 or 5 degrees C. The resulting hyperphagia adequately compensated energy losses as judged from body weight. The cold-induced hyperphagia was accompanied by a non-parallel increase in pancreatic hydrolases. Amylase and lipase were not increased above the adaptive levels they had respectively reached in the heat with a high-starch or high-lipid diet. Chymotrypsinogen, on the contrary, responded to increased intake of both diets. It also responded to the higher protein concentration in the high-fat diet caused by isocaloric replacement of starch by fat. Colipase varied independently of lipase and was increased additively by fat and protein intakes. Consequently, although limiting for lipase in the warm, colipase rose to a 1:1 ratio in the cold. Increased intake had a consistent pleiotropic effect evidenced by an increase of amylase with the high-fat diet and of lipase with the low-fat diet. The net effect was a significant increase in the lipid-digesting potential of the organism of lipid-fed animals upon exposure to cold, while the starch-digesting potential remained unaffected in starch-fed animals.


Asunto(s)
Frío , Grasas de la Dieta/administración & dosificación , Trastornos de Alimentación y de la Ingestión de Alimentos/enzimología , Hidrolasas/metabolismo , Hiperfagia/enzimología , Páncreas/enzimología , Animales , Ingestión de Energía , Humanos , Hiperfagia/etiología , Masculino , Tamaño de los Órganos , Ratas , Ratas Endogámicas
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA